TITLE A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination
AUTHOR Guofang Zhang, Yalin Cong, Feng-Liang Liu, Jiufeng Sun, Jiantian Zhang, Guoli Cao, Lingqiang Zhou, Wenjie Yang, Qingle Song, Fangjun Wang, Ke Liu, Jing Qu, Jing Wang, Min He, Shun Feng, Didar Baimanov, Wei Xu, Rong-Hua Luo, Xin-Yan Long, Shumin Liao, Yunping Fan, Yu-Feng Li, Bai Li, Ximing Shao, Guocheng Wang, Lijing Fang, Huaiyu Wang, Xue-Feng Yu, Yan-Zhong Chang, Yuliang Zhao, Liang Li, Peng Yu, Yong-Tang Zheng, Diana Boraschi, Hongchang Li, Chunying Chen, Liming Wang & Yang Li
YEAR 2022
JOURNAL Nature Nanotechnology

The global emergency caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic can only be solved with effective and widespread preventive and therapeutic strategies, and both are still insufficient. Here, we describe an ultrathin two-dimensional CuInP2S6 (CIPS) nanosheet as a new agent against SARS-CoV-2 infection. CIPS exhibits an extremely high and selective binding capacity (dissociation constant (KD) < 1 pM) for the receptor binding domain of the spike protein of wild-type SARS-CoV-2 and its variants of concern, including Delta and Omicron, inhibiting virus entry and infection in angiotensin converting enzyme 2 (ACE2)-bearing cells, human airway epithelial organoids and human ACE2-transgenic mice. On association with CIPS, the virus is quickly phagocytosed and eliminated by macrophages, suggesting that CIPS could be successfully used to capture and facilitate virus elimination by the host. Thus, we propose CIPS as a promising nanodrug for future safe and effective anti-SARS-CoV-2 therapy, and as a decontamination agent and surface-coating material to reduce SARS-CoV-2 infectivity.

KEYWORDS SARS-CoV-2, Two-dimensional materials
PDF Download List